1Expanded DNA-MVA prime-boost trial begins in UK. IAVI Report, The newsletter on international AIDS vaccine research, 2002, 6(2):1.
2Bass E, Jefferys R. Warming trends at keystone vaccine conference.IAVI Beport The newsletter on international AIDS vaccine research,2002, 6(2):1-2,13.
3Osorio JE, Tondinson CC, Frank BS, et al. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine, 1999,17: 1109-1116.
4Lognaell DL, Parnell MJ, Bailey JR, et 81. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates:comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine, 2002, 20:838-844.
5Leviae MM, Woodrew GC, Kaper JB, et al. New Generation Vaccines.2nd ed. New York: Marcel Dekker Inc,1997.25-34.
6Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine.Vaccine, 2000,18:44-47.
7Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live attenuated dengue vaccines in Thai adult volunteers:role of serotype concentration,ratio,and multiple doses. Am J Trop Med Hyg, 2002,66:264-272.
8Plotkin SA, Qrenstein WA. VACCINES. 3^rd. ed. U S A:W.B.Saunders, 1999. 903-908.
9Lynch M, Bresee JS, Gentsch JR, et al. Rotavirus Vaccines. Current Opinion in Infectious Diseases, 2000,13 : 495-502.
10Brochier B, Boulanger D, Costy F, et al. Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus. Vaccine, 1994,2:1368.
